CStone secures approval in China for clinical trial of CS1001, BLU-554 combo for HCC

Image: CStone received approval to initiate clinical development in China of CS1001 and BLU-554 (CS3008) in combination therapy for HCC. Photo: courtesy of skeeze/Pixabay.